Company Profile

In mid 1992, Scios - also an SBIR involved firm - and the small publicly traded Nova Pharmaceutical Corporation agreed to merge in a stock swap. Nova had been using various new technologies to make chemicals that would treat inflammatory diseases and central-nervous-system disorders. In the late eighties Nova Pharmaceutical Corporation (NASDAQ: NOVX) and the Johns Hopkins Medical Institutions had announced that they had established the key role bradykinin plays in relaying pain messages to the nervous system. This discovery helps pave the way for the development of a whole class of important new drugs that will combat pain without causing addiction.